In today’s healthcare landscape, advanced imaging technologies — CT, MRI, fMRI, PET, and axial ultrasound — have revolutionized diagnosis by providing detailed structural and, in some cases, metabolic views inside the body. These tools are indispensable for confirming diagnoses, staging disease, guiding surgery, and monitoring treatment response. But they primarily capture snapshots — often after significant changes have already occurred — and come with practical limitations, particularly around early detection and safety for frequent use.
A different paradigm is emerging: measuring the human biofield, the dynamic electromagnetic activity generated by the body’s cells. Technologies like Aurorus offer a non-invasive, real-time window into physiological signals at the cellular communication level, well before structural changes are typically visible on conventional imaging. This second post in our series builds on the foundational understanding of the biofield from our previous article, exploring how the Aurorus approach differs from conventional diagnostics, where its research is heading, and what that could mean over time.
Conventional Diagnostics: Strengths and Limitations
These modalities provide critical anatomical and functional data that save lives — that strength isn’t in question. But they also carry real limitations, particularly for prevention, early optimization, frequent monitoring, and capturing subtle physiological signal:
- Resolution limits at the cellular level. Conventional tools have a minimum detection threshold — even advanced PET scanners typically resolve down to about 4–7 mm — meaning they generally cannot visualize the real-time communication and regulatory processes occurring between individual cells.
- Detection threshold and timing. These tools excel at identifying established pathology (visible tumors, significant metabolic shifts, structural damage) but are not designed to capture pre-clinical variation in the body’s regulatory activity.
- Radiation exposure (CT). A 2025 study in JAMA Internal Medicine by Smith-Bindman and colleagues at UCSF projected that the roughly 93 million CT scans performed in the U.S. in 2023 could be associated with approximately 103,000 future cancers (90% uncertainty limits: 96,400–109,500) — and that, if current practices continue, CT-associated radiation could eventually represent about 5% of annual U.S. cancer diagnoses. The study’s authors and an accompanying editorial were clear that these are model-based projections, not direct one-to-one causation, and the estimate has drawn some debate in the radiology community over its assumptions and degree of uncertainty — worth knowing given how widely the headline number has circulated.
- Field strength and RF exposure (MRI). MRI scanners use powerful static magnetic fields (typically 1.5–3 Tesla) combined with radiofrequency pulses that can cause tissue heating. Protocols aim to keep exposures within safe limits, but repeated or whole-body scans raise considerations about cumulative effects.
- Practical drawbacks. High costs, limited accessibility, lengthy procedures, contrast agents in some cases, claustrophobia, and an inability to provide dynamic, real-time regulatory insight.
These tools answer “what is there?” and sometimes “what is it doing at a macroscopic level?” — but they aren’t built to capture the more upstream signals of how cells are coordinating with one another.
The Aurorus Approach: Measuring the Human Biofield in Real Time
Aurorus takes a different approach: non-invasively capturing electrophysiological patterns through a quick fingertip scan. In minutes, it produces a numeric readout that our clinical research program has found to correlate with markers across multiple organ systems — signal that conventional imaging isn’t designed to capture.
A useful way to think about it: Aurorus works like a kind of spectrometer for the biofield — rather than resolving the chemical makeup of a sample, it’s reading the body’s own faint electromagnetic and biophotonic activity.
Core differences:
- Non-invasive & radiation-free: No ionizing radiation, radioactive tracers, or intense magnetic fields — safe for frequent use, screening, and longitudinal monitoring.
- Real-time & dynamic: Captures live field responses and regulatory coherence rather than static images.
- Cellular-level terrain insights: Reveals mitochondrial function, oxidative stress, organ communication, autonomic balance, and overall resilience.
- Whole-system view: Holistic assessment versus targeted anatomical hotspots.
- Accessible: Portable, quick, and suitable for broader clinical and wellness settings.
This makes Aurorus highly complementary to conventional imaging — providing early contextual insights on *why* issues might be developing and how the body is responding at the foundational electromagnetic level.
Current Use: A Complementary Wellness and Research Tool
For individuals and practitioners, biofield measurement currently offers:
- Wellness tracking — a way to observe how the body’s electromagnetic signal changes over time.
- Personalized feedback — objectively tracking how the body responds to interventions and lifestyle changes.
- Research contribution — data that feeds our ongoing studies into clinical correlations.
Aurorus is not currently cleared to diagnose, treat, cure, or prevent any disease, and any Aurorus data should be interpreted by a qualified healthcare professional alongside — never in place of — standard medical evaluation.
Looking Ahead: Aurorus DX and the Future of Field-Based Diagnostics
Aurorus is actively pursuing FDA 510(k) clearance for specific diagnostic indications, building on its existing De Novo Class I clearance (DEN150004) as an electrophysiological measurement device. This is a research and regulatory pipeline, not a current capability.
Indications under research and planned for future submission include:
- Indications under research and planned for future submission include:
- Metabolic syndrome and diabetes
- Traumatic brain injury (TBI)
- Various cancers, as an adjunctive research area
If these pathways bear out, biofield measurement could eventually play a role as an early, complementary signal alongside conventional diagnostics — helping guide when more targeted testing is warranted. That said, regulatory clearance requires rigorous validation, and Aurorus remains a complementary wellness and research tool today, not a diagnostic device.
Why This Matters
Conventional diagnostics excel at structural visualization. Aurorus is researching a different, complementary layer: real-time signal from the body’s electromagnetic activity, at a scale conventional imaging isn’t designed to capture. Together, and pending further regulatory validation, these approaches could eventually offer a more complete picture of health. Explore how biofield assessment might fit into your wellness practice or research program. Visit AurorusDX.com to learn more, and stay tuned for future posts on practical applications and emerging research.
*Disclaimer: This content is for educational purposes only. Aurorus DX technology is currently a complementary tool and not a replacement for standard medical diagnostics or care. FDA 510(k) clearances are in progress for specific indications and are not yet obtained for all mentioned uses. Imaging decisions should always weigh benefits and risks under qualified medical guidance. Individual results may vary.*
End · 5 min
Nancy Rizzo Prior to developing the science and technology for Aurorus, Nancy spent 13 years at Mayo Clinic Scottsdale as a board certified radiological therapeutic physicist and cochaired the Complementary and Alternative Medicine program. Nancy is board certified as a Radiological Therapeutic Physicist by the American Board of Radiology (DABR) and holds a Ph D. in Energy Medicine with an emphasis on Biophysics from Holos University.
Follow →